Equities

Genscript Biotech Corp

Genscript Biotech Corp

Actions
  • Price (EUR)1.32
  • Today's Change0.00 / 0.00%
  • Shares traded4.00k
  • 1 Year change-52.26%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,9281,4631,403
Total Receivables, Net300171167
Total Inventory536044
Prepaid expenses212612
Other current assets, total514413
Total current assets2,3531,7651,639
Property, plant & equipment, net751647505
Goodwill, net1.362.5514
Intangibles, net192426
Long term investments912325
Note receivable - long term0.29----
Other long term assets3.187018
Total assets3,3872,5462,234
LIABILITIES
Accounts payable405630
Accrued expenses166210156
Notes payable/short-term debt57330
Current portion long-term debt/capital leases8.94128.03
Other current liabilities, total223235219
Total current liabilities495546413
Total long term debt351305148
Total debt417350156
Deferred income tax5.628.017.73
Minority interest653352342
Other liabilities, total491325277
Total liabilities1,9961,5361,188
SHAREHOLDERS EQUITY
Common stock2.122.112.10
Additional paid-in capital1,9391,4731,274
Retained earnings (accumulated deficit)(519)(428)(235)
Treasury stock - common(9.45)(12)(16)
Unrealized gain (loss)------
Other equity, total(22)(25)20
Total equity1,3911,0111,046
Total liabilities & shareholders' equity3,3872,5462,234
Total common shares outstanding2,1212,1112,096
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.